HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (3- ethyl- 5- isopropyl- 2,6- dioxo- 1,2,3,6- tetrahydropyrimidine- 4- carbonyl)- 5- methylbenzonitrile

an HIV reverse transcriptase inhibitor; structure in first source

Also Known As:

KM-023

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Imides: 79
  - 3-(3-ethyl-5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-5-methylbenzonitrile: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridones: 14
      - 3-(3-ethyl-5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-5-methylbenzonitrile: 1

Experts

1.	Bray, Brian: 1 article (01/2014)
2.	Cha, Yu-Jung: 1 article (01/2014)
3.	Cho, Joo-Youn: 1 article (01/2014)
4.	Chung, Jae-Yong: 1 article (01/2014)
5.	Kang, Myung-Chol: 1 article (01/2014)
6.	Lim, Kyoung Soo: 1 article (01/2014)
7.	Park, Min-Kyu: 1 article (01/2014)
8.	Schneider, Stephen: 1 article (01/2014)
9.	Yoon, Seo Hyun: 1 article (01/2014)
10.	Yu, Kyung-Sang: 1 article (01/2014)

Related Diseases

1.	Infections 01/01/2014 - "This Phase I clinical trial information can be used to design further clinical studies appropriately to evaluate KM-023 in patients with HIV-1 infection." 01/01/2014 - "KM-023 is a new second-generation nonnucleoside reverse-transcriptase inhibitor that is under development for the treatment of human immunodeficiency virus (HIV) type 1 infection. "

Related Drugs and Biologics

1.	Reverse Transcriptase Inhibitors